Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Trastuzumab
Related studies linked through entity extraction aliases.
Oral Vinorelbine in Combination With Trastuzumab for Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
- Status
- COMPLETED
- Phase
- PHASE3
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
- Status
- COMPLETED
- Phase
- PHASE2
An Observational Study of the Mean Duration of Trastuzumab (Herceptin) Treatment in Participants With Early or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
- Status
- TERMINATED
- Phase
- N/A
Trastuzumab and Vinorelbine in Advanced Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Bevacizumab Added to Trastuzumab Plus Docetaxel in the Neoadjuvant Setting in Participants With Early Stage HER2-Positive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment
- Status
- COMPLETED
- Phase
- PHASE3
Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery
- Status
- COMPLETED
- Phase
- PHASE2
Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE3
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- NA
Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
- Status
- COMPLETED
- Phase
- PHASE3
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
- Status
- COMPLETED
- Phase
- PHASE3